News from the consortium

PCCTC Investigator Andrew J. Armstrong, MD, MS Selected for Rapid Oral Abstract Session at 2026 ASCO Annual Meeting

The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that esteemed PCCTC investigator Andrew J. Armstrong, MD, MS, of Duke University Medical Center and Duke Cancer Institute,…

PCCTC Investigators Present an Impressive and Diverse Slate of Abstracts at ASCO 2026

First Patient Enrolled at Memorial Sloan Kettering Cancer Center in PCCTC-Sponsored TALENT Study Evaluating Novel Treatment Combination for Advanced Prostate Cancer

The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that investigators at Memorial Sloan Kettering Cancer Center (MSK) have enrolled the first patient in the TALENT study, a…

Results of the Phase 2 Trial of Olaparib + Radium-223 vs Radium-223 in Men With CRPC With Bone Metastases (COMRADE) led by the PCCTC’s Dr McKay published in JCO

PCCTC Investigator Dr Andrew Armstrong on PCWG4's Amended Terminology and Biomarker Standards for Advanced Prostate Cancer

First Quadruplet Therapy Regimen Shows Promise for Men with High-Volume Metastatic APMN Prostate Cancer

CASCARA phase 2 trial demonstrates that combining platinum-based combination chemotherapy with dual hormonal treatments is feasible, safe, and shows encouraging early activity New York, NY —…

Dr Sean McBride on the PCCTC-Managed AASUR Trial in High-Risk Prostate Cancer

Advancing the Standard: How the PCCTC Led the Science at the 2026 ASCO GU Symposium and Forged New Paths for Collaboration

Prostate Cancer Working Group 4 Publishes Landmark Recommendations in the Journal of Clinical Oncology

Comprehensive Guidance Document Establishes New Standards for Prostate Cancer Clinical Trial Design in Era of Precision Medicine New York, NY – February 26, 2026 – The Prostate Cancer Clinical…

Landmark Prostate Cancer Trial Shows Combination Therapy More Than Doubles Survival in Metastatic Castration Resistant Prostate Cancer Patients with DNA Repair Defects

PCCTC Investigator Dr. Maha Hussain to Present BRCAAway Trial Results Showing Median Survival Exceeding 5 Years with Abiraterone Plus Olaparib at 2026 ASCO GU Symposium CHICAGO, IL – The Prostate…

Prostate Cancer Working Group 4 Unveils Updated Global Standards for Advanced Prostate Cancer Clinical Trials at 2026 ASCO GU Symposium

New Recommendations Address Modern Imaging, Biomarkers, and Evolving Treatment Landscape The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced the presentation of the Prostate…

PCCTC Investigators Showcase Groundbreaking Research at 2026 ASCO GU Symposium

Multiple Abstracts Highlight The PCCTC's Leadership in Advancing Prostate Cancer Clinical Trials and Treatment Standards The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that…

K36 Therapeutics Completes Dosing of First Cohort in PCCTC-Managed Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer

PCCTC Investigators and Colleagues Highlight the Importance of Racial Diversity in Future Genomic Profiling and Clinical Trials Efforts (Nature)

PCCTC Investigator Dr George on the Role of Radioligand Therapy in Prostate Cancer Management

2026 Summer Internship Program

The PCCTC plans on hiring three summer interns next year to support Data Management, Data Science, and Clinical Operations. The 10-week internships are full-time, paid, 100% remote, and working…

PCCTC Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum

Prespecified Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study

The PCCTC’s Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) Activated

The PCCTC-managed Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After…

PCCTC-managed Phase 1 Study of K36’s Novel NSD2 Inhibitor KTX-2001 Activated

We’re excited to announce the activation of San Antonio, Texas’ USA Clinical Trials as the first site for the PCCTC-managed phase 1 clinical study of K36’s novel NSD2 inhibitor KTX-2001…

Results from Cohorts 4 and 5 of the Phase 2 KEYNOTE-199 Study Published

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPIs: A Multinational Real-World Analysis of the IRONMAN Registry

The PCCTC at ASCO 2025

The Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to announce that science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at this…

Dr. Howard I. Scher Honored with Richard D. Williams, MD Prostate Cancer Research Excellence Award

The PCCTC at SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC

https://www.urotoday.com/conference-highlights/ses-aua-2025/ses-aua-2025-prostate-cancer/158985-ses-aua-2025-phase-1-trial-of-mevrometostat-pf-06821497-a-potent-and-selective-inhibitor-of-ezh2-in-c…

The PCCTC at ASCO GU 2025

Science from seven Prostate Cancer Clinical Trials Consortium (PCCTC) studies will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, CA on February…

Summer Internships Announced

The Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to announce its Summer 2025 internships. Opportunities are available in Data Management, Data Science, and Clinical Operations.…

CDMRP Features PCCTC-Managed PROMISE Registry

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC

Results Published from PCCTC Study of Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy

6th Annual NYC Prostate Cancer Summit to Feature PCCTC Investigators

The Prostate Cancer Clinical Trials Consortium (PCCTC) Receives Gift from Friends and Family Against Prostate Cancer

The Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to announce a philanthropic investment from Friends and Family Against Prostate Cancer to support innovative enhancements to…

Results from the PCCTC-managed Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line mCRPC with DNA Repair Defects (BRCAAway) Study Published in Clinical Cancer Research

The data from this trial supports an advantage of upfront combination therapy with ARP-I + PARP-I versus either single-agent alone in patients with metastatic castration resistant prostate cancer…

American Cancer Society, Trial Library, and the PCCTC Collaborate to Support Recruitment of Black Patients for Clinical Trials

ATLANTA, July 9, 2024 — Today the American Cancer Society (ACS) announced a new collaboration with Trial Library, Inc., and the Prostate Cancer Clinical Trials Consortium (PCCTC) to support a…

PCCTC Investigator Dr. Rana McKay Wins the 2024 Christopher G. Wood Rising Star Award at IKCS Europe

Rana McKay won the 2024 Christopher G. Wood Rising Star Award at IKCS Europe, which took place in Sitges, Spain between April 18th and 20th. About Rana McKay Dr. Rana R. McKay, MD, is a specialist…

OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program

OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mCRPC”) has been dosed in a Phase 1/2 trial evaluating the anti-CTLA-4…

The PCCTC-managed IRONMAN Registry Deepens the Understanding of Racial Disparities in Pain and Survival in Individuals with Advanced Prostate Cancer

Manuscript published in Cancer Research Communications finds Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse…

The PCCTC-managed PROMISE Registry Manuscript Published In The Prostate.

The PROMISE Registry aims to provide access to germline genetic testing and to collect data to understand disease characteristics and treatment responses across the disease spectrum for prostate…

PCCTC Scientific Oversight Committee Chair Reflects on Advances Made in High-Risk, Low-Grade Prostate Cancer Management

With a reflection on the past paradigm-changing studies done in advanced prostate cancer, Howard I. Scher, MD, emphasized that the field needs to shift focus to earlier-stage settings,…

Results from the PCCTC's STREAM Study Led by Rhonda L Bitting, MD of Duke University Published

Study shows that LD and higher ADT sensitivity tumors had favorable outcomes. Those with a luminal proliferating subtype, PTEN loss, and/or HRD signatures had poor outcomes despite ADT/radiation…

Results from the PCCTC’s Randomized Phase 2 Trial of Abiraterone Acetate With or Without Cabazitaxel Published in The Journal of Clinical Oncology

Combination was safe with improved rPFS, OS duration, and a higher proportion ofPSA declines.

Caris Life Sciences, PCCTC, and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic Profiling

IRVING, Texas and SAN DIEGO, June 2, 2022 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions…

Lantheus Collaborates with The PCCTC To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

January 27, 2022 at 8:30 AM EST PDF Version NORTH BILLERICA, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI…

PCCTC Trial Is First to Use Standard Ra-223 Doses, Contemporary Pain Endpoints and PRO Collection Tools

Study published in Clinical Genitourinary Cancer details the first examining radium-223 in pain palliation using standard doses and contemporary pain end points radium-223, and demonstrated…

Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry

The Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure…

The PCCTC Germline Genetics Working Group Publishes New Guidelines

Manuscript published in JCO Oncology Practice details practical considerations and challenges for germline genetic testing in patients with prostate cancer

PCCTC Investigators on the Diversity of Enrollment in Prostate Cancer Clinical Trials

Despite known racial disparities, men of color remain underrepresented in prostate cancer clinical trials

The Transformative Development and Progress of the PCCTC

Dr Charles Ryan is joined by the leadership of the Prostate Cancer Clinical Trials Consortium, a group that has developed innumerable trials and therapies for advanced prostate cancer.

CellCentric Signs Agreement with the PCCTC for Phase II Clinical Trial Expansion Into the US

CellCentric has developed CCS1477, the first p300/CBP inhibitor of its kind, for use in the treatment of multiple cancer types. The drug will transition into Phase II dose expansion clinical…